Woodstock, GA, April 24, 2012 – Tissue Regeneration Technologies, LLC (TRT) today announced that the US patent and Trademark office (USPTO) has issued the company patent number US 8,162,859, titled “Shock Wave Treatment Device and Method of Use”. The patent relates to a side firing, sterile, disposable, hand held probe used in the direct application of shock waves to Ischemic Heart Tissue. TRT, with its cardiology affiliate Cardio Regeneration Technologies (CRT), is the first company worldwide to apply shock waves directly to the human heart. After exhaustive animal studies to establish safety, 10 patients with scarred heart tissue, post-heart attack, were treated with the patented device at the University of Vienna. After treatment, there was strong statistically significant evidence proving substantially improved heart function and quality of life measures. Phase II Trials are now scheduled to begin at the University of Innsbruck, Innsbruck, Austria.